StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Bernstein

BUYZydus Lifesciences Limited

byBernsteinHorizon: NA (inferred 1 year)18 Sept 2026via CNBC Awaaz.

Entry₹1,150.7Inferred
Target₹1,457
Total upside +26.62%
Stop lossNot given
CMP₹1,1601d ago
Active+0.81%+25.60%upside left 12 mo left
Follow Bernstein for new callsGet alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 7 other Long-term calls on ZYDUSLIFESee 99 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 19 Sept, 5:47 pm IST
24 supporting9 neutral5 opposing
Supports the BUY call (24)

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

NewsCnbc-Tv18·18 Sept · yesterday

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·18 Sept · yesterday

India's Pharma Market Expands 10.7% On GLP-1 Launch: Zydus, Glenmark Lead Large-Cap Growth

NewsNdtv-Profit·9 Sept · 1w ago

(opens in new tab)

Zydus Lifesciences announced positive topline results from the completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg for MASH.

BSE · Company Update·31 Aug · 3w ago

(opens in new tab)

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

NewsNdtv-Profit·27 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (9)

Zydus Pharmaceuticals USA Inc., a subsidiary of Zydus Lifesciences, has agreed to pay USD 5.9 million to settle litigation in the US District Court for the Eastern District of Pennsylvania. The settle

BSE · Company Update·5 Sept · 2w ago

(opens in new tab)
Weighs against the BUY call (5)

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·12 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.